Nishijima Saori, Sugaya Kimio, Yamada Tetsuo, Miyazato Minoru, Ogawa Yoshihide
Division of Urology, Department of Organ-oriented Medicine, Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan.
Biomed Res. 2006 Aug;27(4):163-7. doi: 10.2220/biomedres.27.163.
We examined the relationship between the Arg16Gly polymorphism of beta2-adrenoceptor (ADRB2) and the efficacy of tricyclic antidepressant therapy in patients with interstitial cystitis (IC). We studied 55 IC patients and 113 controls. The IC patients were treated with imipramine hydrochloride, and the efficacy of treatment was categorized by patients' satisfaction (no change, fair, or good). Genomic DNA was extracted from the controls and IC patients, and the Arg16Gly polymorphism of ADRB2 was analyzed. The Arg16Gly polymorphism showed a significant difference in prevalence between IC patients and controls, and Arg/Arg was associated with increase in the risk of IC than Arg/Gly or Gly/Gly. Regarding the tricyclic antidepressant therapy, there was a significant difference in the prevalence of this polymorphism between IC patients with no change or a fair response to treatment and controls, and Arg/Arg was associated with decrease in the response rate to tricyclic antidepressant therapy than Arg/Gly or Gly/Gly. Therefore, these results suggest that the Arg16Gly polymorphism of ADRB2 is related to down-regulation of ADRB2 expression in the detrusor muscle, so that the response of IC to tricyclic antidepressant therapy depends on the Arg16Gly polymorphism.
我们研究了β2-肾上腺素能受体（ADRB2）的Arg16Gly多态性与间质性膀胱炎（IC）患者三环类抗抑郁药治疗疗效之间的关系。我们研究了55例IC患者和113例对照。IC患者接受盐酸丙咪嗪治疗，治疗效果根据患者满意度分类（无变化、一般或良好）。从对照和IC患者中提取基因组DNA，并分析ADRB2的Arg16Gly多态性。Arg16Gly多态性在IC患者和对照之间的患病率存在显著差异，与Arg/Gly或Gly/Gly相比，Arg/Arg与IC风险增加相关。关于三环类抗抑郁药治疗，在治疗无变化或反应一般的IC患者与对照之间，这种多态性的患病率存在显著差异，与Arg/Gly或Gly/Gly相比，Arg/Arg与三环类抗抑郁药治疗反应率降低相关。因此，这些结果表明，ADRB2的Arg16Gly多态性与逼尿肌中ADRB2表达的下调有关，因此IC对三环类抗抑郁药治疗的反应取决于Arg16Gly多态性。
